Boston, Massachusetts, United States, March 2025 – April O’Neil has joined Newleos Therapeutics as Senior Director of Human Resources, bringing with her a deep background in HR leadership within the biopharma and research sectors. In this new role, she will lead the company’s people strategy during a pivotal time in its mission to advance first- and best-in-class therapies for neuropsychiatric conditions.
Prior to her appointment at Newleos Therapeutics, April O’Neil held the role of Senior Director of Human Resources at DEM Biopharma, Inc., where she was instrumental in scaling HR systems and culture across the growing biotech company. Her tenure also included a key leadership transition from Director to Senior Director during her time with the company.
Before joining DEM Biopharma, April worked at Verve Therapeutics for over two years, first as Associate Director of Human Resources, and later as Director, People and Talent. At Verve, she focused on talent acquisition, employee engagement, and HR operations for a fast-scaling gene editing firm in cardiovascular therapeutics.
April also spent nearly seven years at the Broad Institute of MIT and Harvard, progressing from Associate HR Business Partner to Senior HR Business Partner. In these roles, she supported scientific research functions, aligning HR initiatives with academic and operational excellence.
Earlier in her career, April served in various HR roles at VPNE Parking Solutions, Beacon Health Strategies, and Adecco, where she honed her expertise in staffing, employee relations, and workforce development.
About Newleos Therapeutics:
Newleos Therapeutics is a clinical-stage biopharmaceutical company focused on transforming treatment for neuropsychiatric disorders. Co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D., the company is developing next-generation, oral small molecule therapies targeting GABAA-γ1, V1a, TAAR1, and GABAA-α5. These investigational drugs offer promise in addressing high unmet needs in anxiety, substance use disorders, and cognitive impairments. Newleos is committed to ushering in a new era—a new “eos”—for patients in mental health.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
